CAMBRIDGE, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, announces new safety and ...
Enrollment in BEACON Trial: 35 sickle cell patients enrolled, with 8 treated with BEAM-101. BEAM-101 Efficacy: Achieved greater than 60% fetal hemoglobin (HbF) induction and reduced sickle hemoglobin ...
Beam Therapeutics announced positive updates on its BEAM-101 treatment for sickle cell disease (SCD) from the BEACON Phase 1/2 clinical trial, with results presented at the European Hematology ...
Beam expects to dose 30 patients by mid-2025 and share additional data from the trial by the end of 2025. EHA Investor Webcast Information Beam will host a conference call and webcast today, June 13, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results